Accelerate and Optimize Your Cell Line Development

During the last decade, production of monoclonal antibodies (mAbs) and recombinant proteins using mammalian cells has led to a boom in the number of biotherapeutic proteins reaching the market. Key elements fueling this growth include the rising demand for effective therapeutics, production of mABs as a cancer treatment strategy and increasing vaccine production efforts.

As this growth continues, the need to reduce cell line development costs and shorten the time to market is more critical than ever.

Download this eBook to:

• Explore key cell line development steps for recombinant proteins and hybridomas
• Uncover the importance of monoclonality from a quality and regulatory perspective
• Discover solutions for various stages of cell line development